Colgate-Palmolive (CL) Q1 2026 earnings review
Top-Line Acceleration Marred by Gross Margin Downgrade and North America Collapse
Colgate-Palmolive delivered a mixed quarter. The top-line story is strong: Organic sales growth accelerated to 2.9%, overcoming a sluggish macro environment and exiting the private label pet business. However, earnings quality is deteriorating. Management's claim of 'broad-based bottom-line growth' is contradicted by a 6% decline in GAAP EPS, largely driven by a massive expansion in restructuring charges. Furthermore, North America operating profit plunged 28%, and management was forced to downgrade its full-year gross margin guidance from 'up' to 'down' due to structural cost pressures. While international markets and Hill's are performing well, the deteriorating profitability in the US and surging reorganization costs suggest a much tougher operating environment than the headline revenue numbers imply.
🐂 Bull Case
Latin America (+5.4% organic) and EMEA (+3.5% organic) delivered excellent top-line results while simultaneously expanding operating margins (EMEA up 160 bps). Emerging markets continue to be Colgate's primary growth engine.
Despite a 0.6% company-wide drag from exiting private label manufacturing and soft broader pet category trends, Hill's delivered 2.1% organic growth and expanded operating margins by 30 bps to 23.4%.
🐻 Bear Case
The North American segment is severely lagging. Net sales fell 1.8%, but the real damage was on the bottom line: operating profit collapsed 28% year-over-year, and operating margin compressed by 590 basis points.
After previously guiding for gross margin expansion in FY26, management officially downgraded the outlook to 'down' for the year. Q1 Base Business gross margin already ticked down 20 bps to 60.6%.
⚖️ Verdict: 🔴
Bearish. Accelerating organic growth is commendable, but a gross margin guidance downgrade, doubling of restructuring costs, and a near 30% collapse in North America operating profit indicate that the cost of driving this revenue is becoming structurally higher.
Key Themes
North America Margins Hit a Wall
Management noted 'broad-based bottom-line growth' in the press release, but the segment data explicitly contradicts this. North America operating profit plummeted from $197M in 25Q1 to $141M in 26Q1 (-28%). The margin compression is severe: dropping 590 bps to 15.8%. Volume declined 3.2% and pricing was relatively flat (+1.0%), suggesting severe negative operating leverage and likely high promotional costs to defend market share.
Gross Margin Outlook Reversing
The company officially cut its FY26 gross profit margin guidance from 'up' to 'down' on both a GAAP and non-GAAP basis. This is a significant Reversing trend. Management previously estimated significant tariff headwinds (up to $200M incrementally in prior quarters), and this downgrade confirms that pricing power (+2.2% total company) and productivity programs are no longer sufficient to fully offset inflation and trade pressures.
Restructuring Bill Doubles Overnight
Colgate abruptly expanded its Strategic Growth and Productivity Program (SGPP). The board approved increasing the estimated cumulative pretax charges to $350M-$550M, up drastically from the $200M-$300M outlined just a few quarters ago. While management projects $200M-$300M in annual savings, the sudden doubling of execution costs crushed Q1 GAAP EPS (-6% YoY) and suggests the organization requires much heavier, more expensive lifting to reach its 2030 targets than originally communicated.
EMEA Firing on All Cylinders
The newly recast EMEA segment was the standout performer for profitability. Sales grew 11.9% as reported (+3.5% organic), driven by balanced volume (+2.2%) and pricing (+1.2%). More importantly, operating profit surged 20% to $266M, driving a 160 bps operating margin expansion. This region is successfully executing premiumization despite a cautious European consumer.
Revenue Growth Management and AI (Macro/Tech)
Colgate continues to successfully use AI-driven Revenue Growth Management (RGM) to optimize price-pack architecture and promotional spending. This tech-driven strategy allowed the company to realize +2.2% pricing globally in Q1 despite a low-inflation environment and cautious consumers, partially offsetting the heavy volume losses in North America.
Prime100 Acquisition Distorting Hill's Volume
While Hill's reported a +0.2% volume growth, this includes a massive 1.9% benefit from the Prime100 fresh pet food acquisition. Excluding this, organic volume was negative. The segment's organic growth (+2.1%) relied entirely on pricing (+3.8%), highlighting that unit demand in the premium pet food category remains sluggish.
Other KPIs
Accelerating. Up 28% from $476 million in 25Q1. Operating cash flow improved significantly to $747M (vs $600M), driven by lower cash tied up in working capital and strong international base business earnings. This covers the $417M dividend comfortably.
Accelerating. Advertising spend increased 10% YoY, outpacing the 8.4% net sales growth. Management is aggressively funding the top line, which makes the gross margin compression and North America profit collapse even more concerning—they are spending heavily but struggling to drop that top-line momentum to the bottom line in the US.
Guidance
Stable. The company maintained its prior guidance. This includes a low-single-digit positive impact from foreign exchange, implying the core volume/pricing growth expectation remains steady.
Decelerating potential. Having achieved 2.9% in Q1, the 1% to 4% range implies management sees potential for deceleration later in the year, likely factoring in prolonged weakness in North American volumes and the exit of the private label pet business.
Reversing. A direct downgrade from previous expectations of 'up'. This reflects the reality of ongoing raw material inflation and tariff implementations overpowering pricing actions and productivity savings.
Stable. Maintained from prior guidance. Q1 delivered 7% growth, meaning the remainder of the year is expected to see slower earnings growth to drag the full-year average down into the low-to-mid range.
Key Questions
North America Bleeding
Operating margin in North America collapsed by nearly 600 basis points. How much of this is structural cost deleverage versus aggressive promotional spending to defend market share, and what is the timeline to stem the bleeding?
Gross Margin Downgrade Components
You downgraded FY26 gross margin to 'down' after previously expecting it to be 'up'. Can you bridge the components of this downgrade? Specifically, how much is driven by new tariffs versus raw material inflation like tallow and palm oil?
SGPP Budget Explosion
The estimated costs for the Strategic Growth and Productivity Program effectively doubled to $350M-$550M just quarters after it was initiated. What new inefficiencies or required investments did you uncover that necessitated such a massive expansion of the restructuring budget?